Available technologies

The Benzodiazepine withdrawal symptom questionnaire (BWSQ)

Reference number: 7994

A well-established, validated and widely-used self-assessment scoring system used in a number of clinical trials involving benzodiazepines.

Overview

Benzodiazepines are a large family of psychoactive drugs used in treating a range of conditions including anxiety, insomnia, seizures, substance withdrawal and can also be administered prior to certain medical or dental procedures to induce amnesia or anaesthesia. Examples of common benzodiazepines include: diazepam (Valium), alprazolam (Xanax), lorazepam (Ativan), temazepam (Restoril), clonazepam (Klonopin) and triazolam (Halcion).

A major concern for patients who have been administered benzodiazepines is the development of adverse symptoms (Benzodiazepine withdrawal syndrome) when the drug is withdrawn, both physical and psychological. In clinical trials, the FDA guidelines require adverse events to be reported by the sponsor, so a means of assessing withdrawal symptoms in participants who have been administered benzodiazepines is necessary.

Benefits

  • The leading tool for assessing benzodiazepine withdrawal symptoms
  • Simple enough for patients to self-administer
  • Validated by use in multiple clinical trials, for over 20 years

Download the datasheet

contact

Alexandra Skeaping

Industry Partnerships and Commercialisation Officer, Medicine

a.skeaping@imperial.ac.uk

+44 (0)20 7594 7021

Contact us about this technology

Subscribe for Licensing Opportunities updates
Keep up to date with new technologies and licensing opportunities coming out of Imperial College London